Quigley Announces Successful Poultry Study of Chickens With Infectious Bronchitis; Plans to Approach the Poultry Industry for Potential Commerc...(ne type of IBV vaccine only protects aga...),Health

A chronological summary of the data from studies conducted to date on QR448(a):

-- The formulation was initially identified as QR441(a) and for its

anti-viral activity against Highly Pathogenic Avian Influenza H5N1.

-- In-vitro anti-viral activity was shown against IBV at maximum effective

non-toxic concentrations of QR448(a).

-- In embryonating eggs, non-toxic concentrations were shown to cause

100fold reductions in IBV titer with no noticeable adverse effects on

embryo developing chicks.

-- The best route of administration of QR448(a) to challenged 2 week old

SPF chicks was by aerosol spray as opposed to direct intranasal or

addition to drinking water.

-- Aerosol spray treatment of 2 week old SPF chickens with QR448(a) 6 or 2

hours before or 2 hours after challenge with IBV abrogates the course

of the disease by lowering the presence of virus in the trachea to

undetectable levels and reducing the severity of lesions in the

trachea.

-- A clear and safe dose response has been determined that provides a

significant log reduction in viral titer in the trachea of 2 week old

SPF chickens treated with QR448(a) 2 hours before or 2 hours after

challenge with IBV.

The Quigley Corporation makes no representation that the U.S. Food and Drug Administration or any other regulatory agency will issue an investigational new animal drug number or allow this compound to be marketed for IBV. Furthermore, no claim is made that the potential medicine discussed here is safe, effective, or approved by the Food and Drug Administration.

About The Quigley Corporation

The Quigley Corporation (Nasdaq:
'/>"/>